MedCity News
April 20, 2025
"In the United States, approximately 275,000 cancer patients receive fluorouracil annually, and it is estimated that 3% develop some degree of toxic reaction. Each year, 1,300 patients experience fatal toxicity. Identifying patients who carry harmful DPYD gene variants through PGx testing before chemotherapy administration is critical for preventing these severe toxicities." - Houda Hachad, PharmD, M.Res
Click here to read more about DPYD testing for safer cancer treatment in MedCity News.